Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Accounts Payable
Samsung Biologics Co Ltd
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Accounts Payable
₩187.3B
|
CAGR 3-Years
66%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Accounts Payable
₩240.7m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Accounts Payable
₩17.7B
|
CAGR 3-Years
32%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Accounts Payable
₩246.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Accounts Payable
₩7.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Accounts Payable
₩1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Accounts Payable?
Accounts Payable
187.3B
KRW
Based on the financial report for Mar 31, 2024, Samsung Biologics Co Ltd's Accounts Payable amounts to 187.3B KRW.
What is Samsung Biologics Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
65%
Over the last year, the Accounts Payable growth was 39%. The average annual Accounts Payable growth rates for Samsung Biologics Co Ltd have been 66% over the past three years , 65% over the past five years .